(Q43977818)

28 November 2017

title

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma (English)

1 reference

28 November 2017

1 reference

9

1 reference

28 November 2017

8

Patrick Hwu

1 reference

28 November 2017

Amanda D Bucheit

1

1 reference

28 November 2017

Erica Syklawer

2

1 reference

28 November 2017

John A Jakob

3

1 reference

28 November 2017

Roland L Bassett

4

1 reference

28 November 2017

Jonathan L Curry

5

1 reference

28 November 2017

Jeffrey E Gershenwald

6

1 reference

28 November 2017

Kevin B Kim

7

1 reference

28 November 2017

Michael A Davies

10

1 reference

28 November 2017

language of work or name

English

0 references

publication date

6 August 2013

1 reference

28 November 2017

1 reference

28 November 2017

volume

119

1 reference

28 November 2017

issue

21

1 reference

28 November 2017

page(s)

3821-3829

1 reference

28 November 2017

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

A landscape of driver mutations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

NRAS mutation status is an independent prognostic factor in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

New strategies in melanoma: molecular testing in advanced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

Melanoma genome sequencing reveals frequent PREX2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28306

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.28306

1 reference

28 November 2017

1 reference